Showing results (7241-7250 of 10,083) with videos related to
Sort By:
Pageof 1,009
Current Pharmaceutical Design|June 24, 2014
Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them allVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.Current Pharmaceutical Design|June 24, 2014
LDL and HDL subfractions, dysfunctional HDL: treatment optionsAntonio Garcia-Rios, Dragana Nikolic, Pablo Perez-Martinez, et al.Current Pharmaceutical Design|June 24, 2014
Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular diseaseVasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.Current Pharmaceutical Design|March 18, 2015
An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?Urs Christen, Edith HintermannCurrent Pharmaceutical Design|February 26, 2015
Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic EffectsMarkus van der Giet, Cornelia Henkel, Mirjam Schuchardt, et al.Current Pharmaceutical Design|March 4, 2015
Review: modifications of human serum albumin and their binding effectPhilbert Lee, Xiaoyang WuCurrent Pharmaceutical Design|March 4, 2015
Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugsYi Gou, Yao Zhang, Feng Yang, et al.Current Pharmaceutical Design|March 4, 2015
Drugs modulate allosterically heme-Fe-recognition by human serum albumin and heme-fe-mediated reactivityAlessandra di Masi, Loris Leboffe, Viviana Trezza, et al.Current Pharmaceutical Design|March 4, 2015
Smart electrospun nanofibers for controlled drug release: recent advances and new perspectivesLin Weng, Jingwei XieCurrent Pharmaceutical Design|March 10, 2015
Predicting the druggability of protein-protein interactions based on sequence and structure features of active pocketsX U Dai, Run Yu Jing, Yanzhi Guo, et al.Pageof 1,009